Austin Institute for Clinical Research
Welcome,         Profile    Billing    Logout  
 15 Trials 
39 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldberg, David
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Completed
3
86
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
PLATyPuS, NCT02315898: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

Completed
2
40
US
Treatment-inhaled tPA, alteplase, Activase
University of Michigan, Genentech, Inc.
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
03/21
06/23
NCT04844840: A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Completed
2
29
US
STP705, STP705 Powder for Injection, Placebo
Sirnaomics
Keloid
05/23
05/23
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Active, not recruiting
2
201
US
Epclusa
University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease
06/25
01/26
LCN RESCU, NCT05832229: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting
2
256
US
Rosuvastatin, Rosuvastatin 20 mg, Rosuvastatin 10 mg
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
11/26
11/26
FALD, NCT03430583: Evaluation of Fontan-Associated Liver Disease

Active, not recruiting
N/A
100
Canada, US
MZ101
Mezzion Pharma Co. Ltd, National Heart, Lung, and Blood Institute (NHLBI)
Single Ventricle Heart Disease
06/21
08/21
RELAX, NCT05457322: The Trial: Nonpharmaceutical Intervention for Nocturnal Muscle Cramps

Completed
N/A
99
US
Behavioral intervention one, Behavioral intervention two
University of Michigan
Cramps, Muscle Cramp
08/23
08/23
NCT05358860: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Completed
N/A
60
US
Sofwave, SUPERB
Sofwave Medical LTD
Acne Scars - Mixed Atrophic and Hypertrophic
12/22
12/22
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/25
12/25
TEST, NCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Recruiting
N/A
360
US
TEST Intervention
University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
07/26
01/27
LCN-C, NCT05740358: Liver Cirrhosis Network Cohort Study

Recruiting
N/A
1200
US
Northwestern University, The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California, Central Virginia Veterans Healthcare System
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
09/27
09/28
FORTE, NCT05080673: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Recruiting
N/A
9500
US
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
NRG Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
11/35
11/65
Rich, Phoebe
NCT06857942: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Overweight or Obesity
10/26
10/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT05135910: To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Active, not recruiting
2a
35
US
Hallux Terbinafine Subungual Gel, HSG
Hallux, Inc.
Onychomycosis of Toenail
09/24
09/24
ASLAN004-003, NCT05158023: Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Completed
2
302
Europe, Canada, US, RoW
Placebo Comparator, ASLAN004
ASLAN Pharmaceuticals
Atopic Dermatitis
06/23
09/23
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

Completed
2
71
US
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Technoderma Medicines Inc., Therapeutics, Inc.
Alopecia, Androgenetic
11/23
01/24
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Recruiting
2
60
US
SM-020 gel 1.0%, Vehicle gel
DermBiont, Inc.
Seborrheic Keratosis
09/24
10/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Couvillion, Megan P
NCT05932732: Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

Completed
4
27
US
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Austin Institute for Clinical Research, The HydraFacial Company
Cutis Laxa Facialis, Xeroderma
10/24
10/24
NCT05203315: Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

Completed
3
21
US
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Austin Institute for Clinical Research, OrthoDermatologics
Plaque Psoriasis
10/23
10/23
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
Schleicher, Stephen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Completed
2
82
US
TLL018 tablets, TLL018 Placeboes
Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
12/24
12/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Thibeaux, J'dah
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24
Doctoroff, Alexander
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Yuengel-Bienenfeld, Christine
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goldberg, David
ADapt, NCT05369403: A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

Completed
3
86
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
01/24
02/25
PLATyPuS, NCT02315898: Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

Completed
2
40
US
Treatment-inhaled tPA, alteplase, Activase
University of Michigan, Genentech, Inc.
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
03/21
06/23
NCT04844840: A Study for Safety and Efficacy Evaluation of Various Doses of STP705 in Reducing Keloid Recurrence

Completed
2
29
US
STP705, STP705 Powder for Injection, Placebo
Sirnaomics
Keloid
05/23
05/23
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
THINKER-NEXT, NCT04075916: A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

Active, not recruiting
2
201
US
Epclusa
University of Pennsylvania, Gilead Sciences, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
End Stage Renal Disease
06/25
01/26
LCN RESCU, NCT05832229: Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

Recruiting
2
256
US
Rosuvastatin, Rosuvastatin 20 mg, Rosuvastatin 10 mg
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
11/26
11/26
FALD, NCT03430583: Evaluation of Fontan-Associated Liver Disease

Active, not recruiting
N/A
100
Canada, US
MZ101
Mezzion Pharma Co. Ltd, National Heart, Lung, and Blood Institute (NHLBI)
Single Ventricle Heart Disease
06/21
08/21
RELAX, NCT05457322: The Trial: Nonpharmaceutical Intervention for Nocturnal Muscle Cramps

Completed
N/A
99
US
Behavioral intervention one, Behavioral intervention two
University of Michigan
Cramps, Muscle Cramp
08/23
08/23
NCT05358860: Safety and Efficacy of Sofwave Treatment for Acne Scars Appearance Improvement

Completed
N/A
60
US
Sofwave, SUPERB
Sofwave Medical LTD
Acne Scars - Mixed Atrophic and Hypertrophic
12/22
12/22
NCT05882721: Treatment for Improvement of Cellulite Appearance Using Form Applicator

Completed
N/A
60
US
Sofwave
Sofwave Medical LTD
Cellulite
11/23
11/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recruiting
N/A
86
Canada, US, RoW
DaRT seeds, DaRT
Alpha Tau Medical LTD.
Recurrent Squamous Cell Carcinoma
12/25
12/25
TEST, NCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant

Recruiting
N/A
360
US
TEST Intervention
University of Pennsylvania, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Liver Transplant; Complications, Cirrhosis, End Stage Liver DIsease, Medication Adherence
07/26
01/27
LCN-C, NCT05740358: Liver Cirrhosis Network Cohort Study

Recruiting
N/A
1200
US
Northwestern University, The Cleveland Clinic, Columbia University, Weill Medical College of Cornell University, Duke University, Mayo Clinic, University of Miami, University of Michigan, University of California, San Diego, University of California, San Francisco, LAC+USC Medical Center, Virginia Commonwealth University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), University of Southern California, Central Virginia Veterans Healthcare System
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis, Biliary, Cirrhosis Cryptogenic, Cirrhosis Due to Hepatitis C, Cirrhosis Due to Primary Sclerosing Cholangitis, Autoimmune Hepatitis
09/27
09/28
FORTE, NCT05080673: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

Recruiting
N/A
9500
US
5-year and 10 Year Surveillance Colonoscopy after Qualifying Colonoscopy
NRG Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
11/35
11/65
Rich, Phoebe
NCT06857942: A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Recruiting
4
200
US
Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Overweight or Obesity
10/26
10/26
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT05135910: To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Active, not recruiting
2a
35
US
Hallux Terbinafine Subungual Gel, HSG
Hallux, Inc.
Onychomycosis of Toenail
09/24
09/24
ASLAN004-003, NCT05158023: Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

Completed
2
302
Europe, Canada, US, RoW
Placebo Comparator, ASLAN004
ASLAN Pharmaceuticals
Atopic Dermatitis
06/23
09/23
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects with Androgenetic Alopecia

Completed
2
71
US
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Technoderma Medicines Inc., Therapeutics, Inc.
Alopecia, Androgenetic
11/23
01/24
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Recruiting
2
60
US
SM-020 gel 1.0%, Vehicle gel
DermBiont, Inc.
Seborrheic Keratosis
09/24
10/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Couvillion, Megan P
NCT05932732: Trial Assessing the Impact on Facial Skin Quality, Hydration, and Skin Barrier of Three (3) Hydrafacial Treatments in Adults of All Skin Types.

Completed
4
27
US
HydraFacial Syndeo System, ReGen-GF, HydraFacial Elite MD System
Austin Institute for Clinical Research, The HydraFacial Company
Cutis Laxa Facialis, Xeroderma
10/24
10/24
NCT05203315: Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults

Completed
3
21
US
Duobrii 0.01 % / 0.045 % Topical Lotion, CeraVe, Topical Cream
Austin Institute for Clinical Research, OrthoDermatologics
Plaque Psoriasis
10/23
10/23
NCT05662202: Study to Evaluate the Safety, Tolerability and Efficacy of BF-200 ALA (Ameluz®) in the Field-directed Treatment of Actinic Keratosis (AK) on the Extremities and Neck/Trunk With Photodynamic Therapy (PDT) Using a RhodoLED Lamp

Active, not recruiting
3
172
US
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratoses
08/25
05/26
NCT04844983: A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC

Completed
2
44
US
STP705, STP705 Powder for Injection, Placebo Saline
Sirnaomics
Squamous Cell Carcinoma in Situ
08/22
12/22
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05060237: Study to Evaluate Safety and Tolerability of BF-200 ALA (Ameluz®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp

Completed
1
112
US
BF-200 ALA and red light LED lamp
Biofrontera Bioscience GmbH
Actinic Keratosis, Keratosis, Actinic, Keratosis
04/23
04/23
Schleicher, Stephen
NCT05310734: PK and Safety Study of Natroba Topical Suspension 0.9% in Subjects 1 Month to 3 Years 11 Months of Age with Scabies

Recruiting
4
50
US
Spinosad Topical, Natroba, benzyl alcohol
Cipher Pharmaceuticals Inc., Concentrics Research, Iqvia Pty Ltd, Medpace, Inc., Inotiv Laboratories, BioAgilytix
Scabies
11/25
03/26
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Completed
2
199
US
NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma, Neurofibromatosis 1
10/23
10/23
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05772520: The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

Completed
2
82
US
TLL018 tablets, TLL018 Placeboes
Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
12/24
12/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
2
350
Europe, Canada, US, RoW
Eltrekibart, LY3041658, Placebo
Eli Lilly and Company
Hidradenitis Suppurativa
08/25
07/26
Thibeaux, J'dah
ASCEND, NCT05295732: The Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

Completed
3
209
Europe, Canada, US
TMB-001, Matching Vehicle
Timber Pharmaceuticals Inc., LEO Pharma
Ichthyosis
06/24
09/24
Doctoroff, Alexander
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Active, not recruiting
2
236
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26
Yuengel-Bienenfeld, Christine
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Active, not recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25

Download Options